未登录

R

Robert Wild

astellas pharmaceuticals

H指数:22

被引数:2,508

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score

NPJ PRECISION ONCOLOGY

IF8

2024-11-110

OAAI

A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death

IF10.1

2024-08-011

PRE

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

SCIENCE ADVANCES

IF12.5

2024-03-2910

OAAI

Pillai, Ray; LeBoeuf, Sarah E.; Hao, Yuan; New, Connie; Blum, Jenna L. E.; Rashidfarrokhi, Ali; Huang, Shih Ming; Bahamon, Christian; Wu, Warren L.; Karadal-Ferrena, Burcu; Herrera, Alberto; Ivanova, Ellie; Cross, Michael; Bossowski, Jozef P.; Ding, Hongyu; Hayashi, Makiko; Rajalingam, Sahith; Karakousi, Triantafyllia; Sayin, Volkan I.; Khanna, Kamal M.; Wong, Kwok-Kin; Wild, Robert; Tsirigos, Aristotelis; Poirier, John T.; Rudin, Charles M.; Davidson, Shawn M.; Koralov, Sergei B.; Papagiannakopoulos, Thales

Targeting pancreatic cancer metabolic dependencies through glutamine antagonism

CANCER RESEARCH

IF16.6

2024-01-160

PRE

Targeting pancreatic cancer metabolic dependencies through glutamine antagonism

通过谷氨酰胺拮抗作用靶向胰腺癌代谢依赖

IF28.5

2023-10-0926

OAAI

Glutamine antagonist DRP-104 enhances anti-tumor responses in KEAP1 mutant lung cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems

MOLECULAR CANCER THERAPEUTICS

IF5.5

2022-08-0542

OA

Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade

CANCER RESEARCH

IF16.6

2020-08-153

PRE

Uncovering metabolic bottlenecks in KEAP1 mutant lung cancer

CANCER RESEARCH

IF16.6

2020-08-151

PRE

RXDX-107 exhibits multiple mechanisms of intracellular delivery and results in extensive drug-induced interstrand crosslinks in solid tumor preclinical models

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Overexpression or inducible expression of Snail, Zeb1 or TGF13 recapitulates epithelial-mesenchymal transition (EMT) in colorectal cancer cell lines in vitro

CANCER RESEARCH

IF16.6

2016-07-150

PRE

A PERK inhibitor that blocks HER2-driven tumorigenesis and suppresses metastasis by targeting single disseminated tumor cells

CANCER RESEARCH

IF16.6

2016-05-260

PRE

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

CANCER DISCOVERY

IF33.3

2016-01-07296

OA

Overexpression of neurotrophic tyrosine receptor kinases (NTRKs) as a potential therapeutic target for cancer

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Discovery of FQIT: An imidazo[5,1-f][1,2,4]triazine derived dual IGF-1R/IR inhibitor

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

MOLECULAR CANCER THERAPEUTICS

IF5.5

2011-08-08182

OAAI

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2010-10-10201

OAAI

Novel strategies for the discovery of plant-derived anticancer agents

PHARMACEUTICAL BIOLOGY

IF4.8

2008-10-20105

OAAI

Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of Alvaradoa haitiensis

JOURNAL OF NATURAL PRODUCTS

IF3.6

2007-06-0722

OAAI

Activity-guided fractionation of the leaves of Ormosia sumatrana using a proteasome inhibition assay

JOURNAL OF NATURAL PRODUCTS

IF3.6

2004-10-1321

PREAI